Skip to main content
Caplight Logo









Eradivir

Eradivir

Private
West Lafayette, IndianaHealthcare & Life Scienceshttps://eradivir.com/

Last Round

Private Placement

Oct 7, 2025

Total Funding Raised

$11.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Eradivir is a biotechnology company that develops immunotherapies to treat viral infections and other diseases using a proprietary small-molecule targeting platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antiviral therapeuticsdrug discoverysmall-molecule drugsbiotechbispecific antigenic immunotherapyBAiTbroad-spectrum antiviralsviral replication inhibitorsdrug developmentbiopharmaclinical-stage biotechtherapeutics platformpharma R&Dbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eradivir Comparables

Compare Eradivir with similar companies based on industry and business-model similarity.

Eradivir comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Via Nova Therapeutics
84%
Cocrystal Pharma Inc
79%
Astremiha Therapeutics
77%

Eradivir Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementOct 7, 2025
Series ASep 23, 2024
GrantSep 18, 2023
GrantFeb 15, 2021
SeedApr 15, 2020

Eradivir Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 75% MoM.

  • Jul 25, 2026

    Monthly visitors increased 54% MoM.

Eradivir Filings

Explore SEC and related filing metadata, where available.

Eradivir filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Eradivir's valuation, stock price, and market status.

Is Eradivir a public or private company?

Eradivir is a private company.

What is the current stock price of Eradivir?

Eradivir is a private company with no public stock price. No recent secondary market data is available.

How much is Eradivir worth (valuation)?

Valuation information for Eradivir is not publicly available.

Can I buy Eradivir stock?

Eradivir shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Eradivir's last funding round?

Eradivir's most recent funding round was VC Round on October 7, 2025.

Who are the main investors in Eradivir?

Key investors in Eradivir include Research Bridge Partners.

Will Eradivir IPO soon?

No public IPO plans have been announced for Eradivir.

How can I track Eradivir secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Eradivir's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWest Lafayette, Indiana
Employee Range28
Year Founded2020
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?